CONNECT WITH US:
linkedin [#161]Created with Sketch.
Explore our easy-to-use
Supplier Directory
Baptist Health Engages Omnicell in an Effort to Enhance Pharmacy Care and Further Gain Control of Medication Supply Chain
Advanced Services for Central Pharmacy Dispensing Designed to Support Dispensing Accuracy and Patient Safety while Improving Clinical and Financial Outcomes
Nov 02, 2023
Pharmacy automation

FORT WORTH, TX - Omnicell, Inc. (Nasdaq: OMCL), a leader in transforming the pharmacy care delivery model, today announced that Kentucky-based Baptist Health has selected Omnicell’s Central Pharmacy Dispensing Service in an effort to address labor challenges and improve clinical and financial outcomes.

Labor shortages, disconnected care settings, and manual processes continue to impact patient care for many healthcare providers and prevent clinicians from operating at the top of their license.

Baptist Health is one of the latest health systems to adopt Omnicell’s Central Pharmacy Dispensing Service, which is expected to help enhance safety and dispensing accuracy while streamlining workflows through a combination of advanced robotics, dispensing optimization tools, and remote and onsite experts. This comprehensive solution is designed to automate and optimize pharmacy labor and workflows, leading to pharmacists spending on average 75 percent less time on dispensing tasks.1

“We selected Omnicell’s robotics and services for our Central Pharmacy Services Center in an effort to help alleviate staffing challenges while focusing on improving quality, patient safety, and efficiency,” said Nilesh Desai, Chief Pharmacy Officer at Baptist Health. “We’re excited about the opportunity to advance further toward our vision of a fully integrated and highly automated pharmacy solution.”

We believe automating central pharmacy tasks is critical to achieving the Autonomous Pharmacy, an industry-defined vision to replace manual, error-prone activities with automated processes that are intended to be safer and more efficient.

“Baptist Health has been a leader in embracing the industry vision of a fully autonomous pharmacy,” said Alex Pratt, senior vice president and chief growth officer for Omnicell. “The addition of these Advanced Services should help them move closer to that vision while also helping to enable them to achieve their goals of optimized clinical and financial outcomes.”

Learn more about Omnicell’s Advanced Services and the transformation of pharmacy care at omnicell.com.

About Baptist Health

Founded in 1924 in Louisville, Kentucky, Baptist Health is a full-spectrum health system dedicated to improving the health of the communities it serves. The Baptist Health family consists of nine hospitals, employed and independent physicians, and more than 400 points of care, including outpatient facilities, physician practices and services, urgent care clinics, outpatient diagnostic and surgery centers, home care, fitness centers, and occupational medicine and physical therapy clinics.

Baptist Health’s eight owned hospitals include more than 2,300 licensed beds in Corbin, Elizabethtown, La Grange, Lexington, Louisville, Paducah, Richmond and New Albany, Indiana. Baptist Health also operates the 410-bed Baptist Health Deaconess Madisonville in Madisonville, Kentucky in a joint venture with Deaconess Health System based in Evansville, Indiana. Baptist Health employs more than 22,500 people in Kentucky and surrounding states.

Baptist Health is the first health system in the U.S. to have all of its hospitals recognized by the American Nursing Credentialing Center with either a Magnet® or Pathway to Excellence® designation for nursing excellence.

Baptist Health’s employed provider network, Baptist Health Medical Group, has more than 1,650 providers offering care in 74 specialties, including more than 780 physicians and more than 870 advanced practice clinicians. Baptist Health’s physician network also includes more than 2,000 independent physicians.

Learn more at BaptistHealth.com.

About Omnicell

Since 1992, Omnicell has been committed to transforming the pharmacy care delivery model in an effort to optimize financial and clinical outcomes across all settings of care. Through a comprehensive portfolio of automation and advanced services, Omnicell is uniquely positioned to address evolving healthcare challenges, connect settings of care, and streamline the medication management process. Healthcare facilities worldwide partner with Omnicell to help increase operational efficiency, reduce medication errors, improve patient safety, and enhance patient engagement and adherence, helping to reduce costly hospital readmissions. To learn more, visit omnicell.com.

OMNICELL and the Omnicell logo are registered trademarks of Omnicell, Inc. or one of its subsidiaries.

Latest Industry news
View all Industry News
3 bottles of Ocrevus
FDA Approves OCREVUS ZUNOVO™: First Twice-Yearly 10-Minute Injection for MS
Sep 17, 2024

Roche recently announced that the United States Food and Drug Administration (U.S. FDA) has approved OCREVUS ZUNOVO™ (ocrelizumab & hyaluronidase-ocsq) for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). OCREVUS ZUNOVO is the first and only twice-a-year, healthcare professional (HCP)-administered approximately 10-minute subcutaneous (SC) injection approved for both these forms of multiple sclerosis, giving people living with MS more treatment options.

Lilly logo
Once-Weekly Insulin Efsitora Alfa Matches Daily Insulin in A1C Reduction for Adults with Type 1 Diabetes
Sep 15, 2024

INDIANAPOLIS, IN - Eli Lilly and Company announced detailed results from the QWINT-5 phase 3 trial evaluating once-weekly insulin efsitora alfa (efsitora) compared to once-daily insulin degludec in adults with type 1 diabetes who require daily basal and multiple daily mealtime insulin injections.

Tremfya box
TREMFYA® (guselkumab) receives U.S. FDA approval for adults with moderately to severely active ulcerative colitis
Sep 12, 2024

HORSHAM, PA - Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has approved TREMFYA® (guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis (UC), a chronic disease of the large intestine in which the lining of the colon becomes inflamed. TREMFYA® is the first and only approved fully-human, dual-acting monoclonal antibody that blocks IL-23 while also binding to CD64, a receptor on cells that produce IL-23.